Osteosarcoma or bone cancer is a type of cancer were bone tissues show an abnormal growth. Osteosarcoma that spreads from initially affected area to distant site is known as metastatic osteosarcoma. Metastatic osteosarcoma often spreads to lungs, whereas less commonly spreads to other bones, brain or other organs. Symptoms of metastatic osteosarcoma varies based on the location of tumor, for example bone pain, bone fracture, swelling, redness, limping, and limited joint movement. If the tumor spreads to the lungs the symptoms include chest pain, shortness of breath, cough with blood, chronic coughing or wheezing. Diagnostic tests for metastatic osteosarcoma includes CT-scan, MRI, X-ray, PET scan, biopsy, and bone scan. Treatment of metastatic osteosarcoma involves surgery, radiation, chemotherapy, biological therapy or a combination of these treatments. Combinational treatment also known as multi-modality treatment is more preferred by medical practitioners to increase treatment outcomes or to prolong survival.
Metastatic Osteosarcoma Treatment Market – Drivers
Increasing drug pipeline for malignant bones and soft tissue (Ewing Sarcoma) cancer is expected to drive growth of metastatic osteosarcoma treatment market. For instance, in 2017, Merck & Co., Inc., studies the effects of Pembrolizumab (MK-3475) in patients with relapsed or metastatic osteosarcoma and reported that these patient are not eligible for curative surgery. Currently, study is in phase II clinical trial and is expected to be marketed in 2023. Moreover, Novartis entered into phase II clinical trials for pazopanib for treatment of metastatic osteosarcoma as of March 2018.
Emerging new therapies for metastatic osteosarcoma treatment will further propel growth of the market. For instance, clinical trials for immunotherapy-based drugs and targeted drug therapy is expected to be a preferred option in the near future, owing to less side-effects. The immune therapy drug called immune checkpoint inhibitors can recognize and attack cancer cells exhibiting better outcomes for other cancer types and also studies have showed it is also effective for osteosarcoma treatment. Moreover, engineered monoclonal antibodies are used to stop cancer growth by hampering new blood vessel formation or to inhibit tumor cells by targeting mTOR protein. For instance, Aadi, LLC studies Nivolumab (Opdivo) in combination with ABI-009 (Nab-rapamycin, the mTOR inhibitor) for potential anti-tumor activity for Ewing Sarcoma. The study is in phase II clinical trial, which is expected to complete by 2020.
In case of pediatric osteosarcoma, around 35% of patient fail first-line of therapy, leading to recurrence in metastatic osteosarcoma in lungs. Therefore, development of novel drugs for treatment of lung cancer, due to metastatic osteosarcoma will also contribute to growth of the metastatic osteosarcoma treatment market. For instance, in 2013, Elesion Pharmaceuticals LLC, a pharmaceutical company developing life-saving therapeutics for rare cancers, entered into phase II clinical trials for Inhaled Lipid-complexed Cisplatin (ILC), a novel sustained release formulation of cisplatin in a nanoscale lipid based complex, for pediatric patients with osteosarcoma metastases for lungs. Additionally, inorganic marketing strategies adopted by metastatic osteosarcoma drug market players is expected to aid in the market growth. For instance, in the same year, Inhaled Lipid-complexed Cisplatin orphan drug designation by European Medicines Agency for the treatment of osteosarcoma. Furthermore, in 2015, company entered in partnership with Intelgen Limited, a Hong Kong-based biopharmaceutical company, for specialized novel anti-cancer drug development and commercializing ILC in Chinese market. Moreover, in 2014, Oncolytics Biotech, examined safety and efficacy of Reolysin for the treatment of bone and soft tissue sarcoma metastatic for lungs.
Metastatic Osteosarcoma Treatment Market – Restrain
Growth of the metastatic osteosarcoma treatment market can be hindered by availability of alternative therapies such as new forms of radiation therapy (intensity-modulated radiation therapy, stereotactic radiosurgery or conformal proton beam therapy). Moreover, stringent approval policies for varies drug therapies is also expected to adversely affect growth of the market.
Metastatic Osteosarcoma Treatment Market - Regional Analysis
Based on geography, the metastatic osteosarcoma treatment market has been segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in the global metastatic osteosarcoma treatment market over the forecast period, owing to increasing research and developmental activities and increasing pipeline products by market players such as Novartis and Merck & Co. Inc. Moreover, high osteosarcoma incidence contribute to the share. For instance, in 2016, American Society of Clinical Oncology (ASCO), estimated 1,000 people to be diagnosed with osteosarcoma each year. However, Asia Pacific is expected to witness fast growth in metastatic osteosarcoma treatment market, due to increasing incidence of osteosarcoma in the region.
Metastatic Osteosarcoma Treatment Market – Competitor
Key players operating in the metastatic osteosarcoma treatment market are Mylan Laboratories Limited, Actavis Inc., Alvogen Inc., Gland Pharma Limited, Sagent Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Dr Reddy’s Laboratories Ltd., and Luitpold Pharmaceuticals Inc.
Metastatic Osteosarcoma Treatment Market - Taxonomy
By Drug Type
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies